Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

(2012) H. L. Kindler et al.   ANNALS OF ONCOLOGY

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

(2012) Haruyasu Murakami et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors

(2011) Giorgio V. Scagliotti et al.   CANCER TREATMENT REVIEWS

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

(2009) P. J. Beltran et al.   MOLECULAR CANCER THERAPEUTICS

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

(2008) S. John Weroha et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer

(2008) P. D. Ryan et al.   ONCOLOGIST